The FDA has officially announced the end of the nationwide shortage of Ozempic and Wegovy, medications used for managing diabetes and aiding weight loss. The announcement follows confirmation from Novo Nordisk that all dosages of its semaglutide product are now available nationwide, fulfilling U.S. demand. The drugmaker invested $6.5 billion to increase manufacturing capacity. Additionally, compounding pharmacies will continue to produce copies of semaglutide until April and May 2024. There are ongoing discussions to address counterfeit medications, indicating continued vigilance in ensuring drug availability and safety.
This update comes after ongoing dialogue with the FDA, and substantial efforts by Novo Nordisk to increase manufacturing capacity...
Collection
[
|
...
]